132 reports of this reaction
1.4% of all ALLANTOIN reports
#18 most reported adverse reaction
HYPONATRAEMIA is the #18 most commonly reported adverse reaction for ALLANTOIN, manufactured by Skinfix, Inc.. There are 132 FDA adverse event reports linking ALLANTOIN to HYPONATRAEMIA. This represents approximately 1.4% of all 9,609 adverse event reports for this drug.
Patients taking ALLANTOIN who experience hyponatraemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPONATRAEMIA is a less commonly reported adverse event for ALLANTOIN, but still significant enough to appear in the safety profile.
In addition to hyponatraemia, the following adverse reactions have been reported for ALLANTOIN:
The following drugs have also been linked to hyponatraemia in FDA adverse event reports:
HYPONATRAEMIA has been reported as an adverse event in 132 FDA reports for ALLANTOIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPONATRAEMIA accounts for approximately 1.4% of all adverse event reports for ALLANTOIN, making it a notable side effect.
If you experience hyponatraemia while taking ALLANTOIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.